India Intravenous Anesthetic Market, by Type (Barbiturates, Ketamine, Benzodiazepines, Propofol, and Others) and by End User (Hospitals, Clinics, and Others) is estimated to be valued at US$ 65.0 million in 2019 and is expected to exhibit a CAGR of 2.6% over the forecast period (2019-2027), as highlighted in a new report published by Coherent Market Insights.
Intravenous anesthetics are a group of fast-acting compounds that are used to induce complete sedation. Some of the important intravenous anesthetics include propofol, etomidate, ketamine, and barbiturates. The increasing number of surgeries in India is a key factor that is expected to drive growth of the India intravenous anesthetic market over the forecast period. Moreover, increasing number of heart disease in India is one of the key factor that leads to rising number of different surgeries in India. For instance, according to the CADI Research Foundation data, in 2010, around 47 million Indians suffered from coronary artery disease (CAD). Moreover, around 60,000 coronary bypass surgeries are performed every year in India. Such high number of surgeries performed in India is expected to fuel growth of the India intravenous anesthetic market.
Fill the form for an exclusive sample of this report@ https://www.coherentmarketinsights.com/insight/request-pdf/3558
Increasing adoption of surgical robots made advancement in surgical procedures which is expected to fuel growth of the India intravenous anesthetic market over the forecast period. Advancements in surgical products and technologies have led to shift from conventional surgeries to minimally invasive surgeries. The usage of robotic technology conducting minimally invasive surgeries has resulted in significant changes in surgical procedures. The acceptance of robotic surgeries increased the number of surgeries performed in India. Moreover, these increasing surgeries are expected to drive growth of the India intravenous anesthetic market over the forecast period.
Browse 13 Market Data Tables and 11 figures spread through 82 pages and in-depth TOC on ‘India intravenous anesthetic market, Forecast to 2027’
To know the latest trends and insights related to India intravenous anesthetic market Press Release, click the link below: https://www.coherentmarketinsights.com/press-release/india-intravenous-anesthetic-market-2880
Key Takeaways of the India intravenous anesthetic market:
- India intravenous anesthetic market is expected to exhibit a CAGR of 2.6% over the forecast period (2019-2027), owing to increasing number of surgeries performed in India
- Among type, propofol segment is expected to hold a dominant position in the India intravenous anesthetic market, owing to high adoption of propofol by Indian healthcare professional for anesthetic procedure
- Major players operating in the India intravenous anesthetic market include AstraZeneca Plc, Fresenius Kabi, AbbVie Inc., Baxter International Inc., B. Braun Melsungen AG, Maruishi Pharmaceutical Co., Ltd, Piramal Healthcare, Hikma Pharmaceuticals, and Mylan N.V.
Purchase this Report (Price 4500 USD for Single-User License) @ https://www.coherentmarketinsights.com/insight/buy-now/3558
- India Intravenous Anesthetic Market, By Type:
- India Intravenous Anesthetic Market, By End User:
- Company Profiles
- AstraZeneca Plc*
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Fresenius Kabi
- AbbVie Inc.
- Baxter International Inc.
- Braun Melsungen AG
- Maruishi Pharmaceutical Co.,Ltd
- Piramal Healthcare
- Hikma Pharmaceuticals
- Mylan N.V.
- AstraZeneca Plc*
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.
Name: Mr. Shah
Coherent Market Insights 1001 4th Ave,
# 3200 Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN : +050-5539-1737